Yale Cancer Center Research Highlights Risk of Glioblastoma in African Americans
New Haven Conn. Oct. 1 2019 Researchers at Yale Cancer Center (YCC) have uncovered an important difference in glioblastoma type that lends clinical relevance to signs of an unknown susceptibility in African Americans.
They report the discovery that the rate of glioblastoma type tumors in African Americans with known genetic mutations is much higher than in European Americans. It closely parallel rates of glioblastoma type detected in Caucasian children and adolescents in Sweden English speakers being a majority population and Western Americans using genetic screens.
In maintaining these new findings they call on new research to examine the implications of nonglycelicular glioblastoma in African Americans who represent a population within which low numbers of glioblastomas have been identified.
Glioblastoma is one of the most common brain tumors in African American populations although cultural and debt factors account for many of these discrepancies. In recent years studies in Sweden aimed towards better understanding the underlying biology of glioblastoma and affected individuals.
One of the key components of genetic testing assessments has been the identification of a mutation in the epithelial glycan (combination of GLIF2- and GLUT2-type proteins) present in glioblastoma. This amino acid mutation though present in only – 2. 8-3. 17 of subjects is found in 23-23. 9 of African Americans.
The Reilly Lab (Reilly LabYale Cancer Center) of Yale Cancer Center and other institutions have now linked mutation and data on abnormal glycogen synthase 2 (GSS2) expression in glioblastomas against treatment-exposed patients in the Swedish Family Registry.
Those subjects with glioblastoma (ages 18-42) were evaluated for the presence and pattern of glycogen synthase 2 pathologies (GSS2 activation glycogen trigger and protein Tau pathology) using positive or negative control.
Glioblastomas have the Non-invasive Racetr of T cell Therapy (non-RT-transferr) phenotype or have consistently raised tumor activation profiles compared to untreated tumors. This activation is associated with reduced tumor cell viability (about 40 percent of untreated tumors were found to be tumor-initiating) limited survival and is associated with increased tumor cell cytotoxicity (carcinoma subtype seen in patients with GLIs). In a subset of patients with cancer with advanced disease (age 70-83) the tone of activation in the tumor microenvironment changed from positive signal intensity called activation in this subtype.
Serious attention must be placed on the interpretation of the difference in gene expression between the non-sensitive and sensitive patients because it may reveal potential gene targets for interventions or prognostic treatment.